Trial reportNutrients2021
Efficacy of a Low-Dose Diosmin Therapy on Improving Symptoms and Quality of Life in Patients with Chronic Venous Disease: Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05750563 (Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre, Interventional Clinical Trial to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus in the Symptomatic Treatment of Haemorrhoids), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre, Interventional Clinical Trial to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus in the Symptomatic Treatment of Haemorrhoids
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.Nutrients · 2021Trial
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
- A nutraceutical intervention for alleviating tired and heavy legs in healthy subjects: a randomized, double-blind, controlled study.BMC nutrition · 2025Article
- Combined Effects of Diosmin, Hesperidin,International journal of molecular sciences · 2025Article
- Article
- Quercetin, Catechin, and Diosmin as Modulators of Haloperidol-HSA Interactions: A Biophysical and Computational Study.International journal of molecular sciences · 2025Article
- Diosmin Administration Slightly Counteracted the Changes in Bone Mechanical Properties Induced by Experimental Type 1 Diabetes in Rats.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy.Food science & nutrition · 2024Review
- Fabrication of diosmin loaded food-grade bilayer nanoparticles with modified chitosan and soy peptides and antioxidant properties examination.Food chemistry: X · 2024Article
- Quality of Life in Chronic Venous Disease: Bridging the Gap Between Patients and Physicians.Clinical drug investigation · 2023Review
- The Impact of Hot Spring Hydrotherapy on Pain Perception and Dysfunction Severity in Patients with Chronic Low Back Pain: A Systematic Review and Meta-Analysis.Journal of pain research · 2023Article
- Potential and Therapeutic Roles of Diosmin in Human Diseases.Biomedicines · 2022Review
- Nutraceuticals for Peripheral Vestibular Pathology: Properties, Usefulness, Future Perspectives and Medico-Legal Aspects.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic Venous Disease (CVD) is a common medical condition affecting up to 80% of the general population. Clinical manifestations can range from mild to more severe signs and symptoms that contribute to the impairment of the quality of life (QoL) of affected patients. Among treatment options, venoactive drugs such as diosmin are widely used in the symptomatic treatment in all clinical stages. The aim of this study is to determine the effectiveness of a new formulated diosmin in relieving symptoms and improving QoL in patients suffering from CVD. In this randomized, double-blind, placebo-controlled, multicenter clinical study, CVD patients with a Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification system between C2 and C4 were randomized to receive a bioavailable diosmin (as μsmin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.